The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Phoebe Tan - Jefferies LLC - Analyst
: Great. Thank you for that intro. So starting with INGREZZA, for your full-year guide, you're saying $2.5 billion to $2.55 billion, which
implies a low growth rate quarter over quarter of negative 6% to 1%. Can you talk about the dynamics there in terms of -- I know
there was one extra week in Q3. But just kind of expectations there and the pricing dynamics.
Question: Phoebe Tan - Jefferies LLC - Analyst
: Great. And then just to confirm for Q4 and Q3, there's a 5% negative impact on pricing. And how should we expect that to continue
into 2026?
Question: Phoebe Tan - Jefferies LLC - Analyst
: Okay. Great. And can you talk about kind of the dynamics that made you result in increasing access and kind of the pricing impact
there?
Question: Phoebe Tan - Jefferies LLC - Analyst
: Great. And do you think that any part of that sort of strategy was kind of anticipation of the IRA and kind of trying to get more patients
on to INGREZZA? And I know that Teva has kind of mentioned on their Q2 -- on their Q3 call that they still keep their long-term
guidance for AUSTEDO.
So it kind of seems based on our calculations that the IRA pricing for them is maybe not as impactful as some people might be
concerned about. So any comments on your expectations there and how you expect to kind of be treated through now and through
your 2029?
Question: Phoebe Tan - Jefferies LLC - Analyst
: Great. So just two follow-up questions here. So first, is it fair then to assume that for 2026, it's flat sort of pricing? Then 2027, 2028,
there's some incremental decline for INGREZZA?
Question: Phoebe Tan - Jefferies LLC - Analyst
: Okay. Very helpful. And then my second follow-up question was for AUSTEDO. I think something that has kind of going under the
radar is the much more higher price of XR. How much do you think that contributes to their expectations that they continue the
long-term growth? And also how much you think that contributes to the market share dynamics that you see in Q3 and based on
full-year guide at around 53% to 55% market share to INGREZZA?
Question: Phoebe Tan - Jefferies LLC - Analyst
: Okay. Great. Thank you, Kyle. Moving on to CRENESSITY just briefly. Right now, it looks like the launch is outpacing INGREZZA actually
at its time of launch. So I guess, just commentary on how launch is doing and kind of your expectations for patient adds going
forward.
Question: Phoebe Tan - Jefferies LLC - Analyst
: So touching on that, do you expect to see sort of a similar dynamic that you see when you increase INGREZZA's sales force? Or too
early to say?
Question: Phoebe Tan - Jefferies LLC - Analyst
: Okay. Great. Thank you for that. And quickly before I run out of time, touching on pipeline. Recently, you announced that NBI-'770
didn't meet the primary endpoint, but you're still looking at next steps. Can you provide some color on kind of what you saw in the
data? Is it safety related? And why -- kind of what you're thinking about for next steps?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 18, 2025 / 12:00PM, NBIX.OQ - Neurocrine Biosciences Inc at Jefferies Global Healthcare Conference
Question: Phoebe Tan - Jefferies LLC - Analyst
: Okay. And two last questions or just one. I guess, where do you see '770 versus osavampator in the space for MDD? And then lastly,
if you have any comments on your TransThera deal, and any future thoughts on BD?
Question: Phoebe Tan - Jefferies LLC - Analyst
: Great. Thank you so much.
| 
